Examining the role of oxytocin in the interoceptive effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') using a drug discrimination paradigm in the rat

Addiction Biology

Volumn 16, Issue 2, 2011, Pages 202-214

  Broadbear, Jillian H ^a   Tunstall, Brendan ^a   Beringer, Katherine ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Amphetamine; drug discrimination; imipramine; MDMA; oxytocin; rat

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; ATOSIBAN; CARBETOCIN; IMIPRAMINE; OXYTOCIN; OXYTOCIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISCRIMINATION; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TASK PERFORMANCE; TREATMENT RESPONSE;

ADRENERGIC UPTAKE INHIBITORS; ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; AMPHETAMINE; AMPHETAMINE-RELATED DISORDERS; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BRAIN; CONDITIONING (PSYCHOLOGY); CUES; DISCRIMINATION LEARNING; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HORMONE ANTAGONISTS; IMIPRAMINE; MALE; MOTIVATION; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXYTOCIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OXYTOCIN; SYNAPTIC TRANSMISSION; VASOTOCIN;

EID: 79952514962     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2010.00267.x     Document Type: Article

References (50)

1. Allott K, Redman J, (2007) Are there sex differences associated with the effects of ecstasy/3,4-methylenedioxymethamphetamine (MDMA)? Neurosci Biobehav Rev 31: 327-347. (Pubitemid 46241449)
2. Argiolas A, Gessa GL, (1991) Central functions of oxytocin. Neurosci Biobehav Rev 15: 217-231.
3. Arletti R, Bertolini A, (1987) Oxytocin acts as an antidepressant in two animal models of depression. Life Sci 41: 1725-1730. (Pubitemid 18013802)
4. Bagdy G, Kalogeras KT, (1993) Stimulation of 5-HT1A and 5-HT2/5-HT1C receptors induce oxytocin release in the male rat. Brain Res 611: 330-332. (Pubitemid 23159703)
5. Baker LE, Taylor MM, (1997) Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination. Pharmacol Biochem Behav 57: 737-748. (Pubitemid 27334421)
6. Baumann MH, Wang X, Rothman RB, (2007) 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology 189: 407-424. (Pubitemid 44791212)
7. Caligioni CS, Franci CR, (2002) Oxytocin secretion induced by osmotic stimulation in rats during the estrous cycle and after ovariectomy and hormone replacement therapy. Life Sci 71: 2821-2831.
8. Callaghan PD, Owens A, Javors MA, Sanchez TA, Jones DJ, Irvine RJ, Daws LC, (2007) In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function. J Neurochem 100: 617-627. (Pubitemid 46098874)
9. Callahan PM, Appel JB, (1988) Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline. J Pharmacol Exp Ther 246: 866-870.
10. Camí J, Farré M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R, (2000) Pharmacology of 3,4-methylenedioxymeth-amphetamine ('ecstasy'): psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455-466. (Pubitemid 30463762)
11. Chaviaras S, Mak P, Ralph D, Krishnan L, Broadbear JH, (2010) Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test. Psychopharmacology 210: 35-43.
12. de la Garza R, Fabrizio KR, Gupta A, (2007) Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns. Psychopharmacology 189: 425-434. (Pubitemid 44791213)
13. Domes A, Heinrichs M, Gläscher J, Büchel C, Braus DF, Herpertz SC, (2007) Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry 62: 1187-1190. (Pubitemid 350029722)
14. Dumont GJ, Verkes RJ, (2006) A review of acute effects of 3,4-methylenedioxy-methamphetamine in healthy volunteers. J Psychopharmacol 20: 176-187.
15. Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ, (2002) The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135: 649-656. (Pubitemid 34177642)
16. Gimpl G, Postina R, Fahrenholz F, Reinheimer T, (2005) Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin. Eur J Pharmacol 510: 9-16. (Pubitemid 40312384)
17. Glennon RA, Misenheimer BR, (1989) Stimulus effects of N-monoethyl-1-(3,4- methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4- methylenedioxyphenyl)-2-aminopropane (N-OH MDA) in rats trained to discriminate MDMA from saline. Pharmacol Biochem Behav 33: 909-912. (Pubitemid 19284309)
18. Glennon RA, Young R, (1984) Further investigation of the discriminative stimulus properties of MDA. Pharmacol Biochem Behav 20: 501-505. (Pubitemid 14138035)
19. Goodwin AK, Baker LE, (2000) A three-choice discrimination procedure dissociates the discriminative stimulus effects of d-amphetamine and (+-)-MDMA in rats. Exp Clin Psychopharmacol 8: 415-423.
20. Goodwin AK, Pynnonen DM, Baker LE, (2003) Serotonergic-dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination. Pharmacol Biochem Behav 74: 987-995. (Pubitemid 36351662)
21. Green AR, Gabrielsson J, Marsden CA, Fone KCF, (2009) MDMA: on the translation from rodent to human dosing. Psychopharmacology 204: 375-378.
22. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI, (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55: 463-508. (Pubitemid 37013213)
23. Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U, (2003) Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 54: 1389-1398. (Pubitemid 37522163)
24. Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S, (2007) Oxytocin increasesretention of social cognition in autism. Biol Psychiatry 61: 498-503. (Pubitemid 46185336)
25. Huber D, Veinante P, Stoop R, (2005) Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 308: 245-248. (Pubitemid 40558858)
26. Johanson CE, Kilbey M, Gatchalian K, Tancer M, (2006) Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 81: 27-36. (Pubitemid 41682476)
27. Johnson MP, Hoffman AJ, Nichols DE, (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132: 269-276. (Pubitemid 17003469)
28. Jorgensen H, Riis M, Knigge U, Kjaer A, Warberg J, (2003) Serotonin receptors involved in vasopressin and oxytocin secretion. J Neuroendocrinol 15: 242-249. (Pubitemid 36266891)
29. Kamien JB, Bickel WK, Hughes JR, Higgins ST, Smith B, (1993) Drug discrimination by humans compared with nonhumans: current status and future directions. Psychopharmacology 111: 259-270. (Pubitemid 23165254)
30. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E, (2005) Oxytocin increases trust in humans. Nature 435: 673-676. (Pubitemid 40825511)
31. Landgraf R, Neumann ID, (2004) Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol 25: 150-176. (Pubitemid 39642188)
32. Li Q, Levy AD, Cabrera TM, Brownfield MS, Battaglia G, Van de Kar LD, (1993) Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT1A agonist, 8-OH-DPAT, in male rats. Brain Res 630: 148-156. (Pubitemid 23342836)
33. Lim MM, Young LJ, (2006) Neuropeptidergic regulation of affiliative behavior and social bonding in animals. Horm Behav 50: 506-517. (Pubitemid 44307118)
34. Manning M, Miteva K, Pancheva S, Stoev S, Wo NC, Chan WY, (1995) Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with atosiban. Int J Pept Protein Res 46: 244-252.
35. Meisenberg G, (1981) Short-term behavioural effects of neurohypophyseal hormones: pharmacological characteristics. Neuropharmacology 21: 309-316.
36. Morley KC, Arnold JC, McGregor IS, (2005) Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Prog Neuropsychopharmacol Biol Psychiatry 29: 648-657. (Pubitemid 40897772)
37. Nutt DJ, (2002) The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol 17: S1-S12. (Pubitemid 34686780)
38. Oberlender R, Nichols DE, (1988) Drug discrimination studies with MDMA and amphetamine. Psychopharmacology 95: 71-76.
39. Onaka T, Ikeda K, Yamashita T, Honda K, (2003) Facilitative role of endogenous oxytocin in noradrenaline release in the rat supraoptic nucleus. Eur J Neurosci 18: 3018-3026. (Pubitemid 38021543)
40. Samson WK, Mogg RJ, (1990) Oxytocin as part of stress responses. Curr Top Neuroendocrinol 10: 33-60.
41. Schechter MD, (1988) Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Biochem Behav 31: 817-824. (Pubitemid 19274289)
42. Tancer M, Johanson CE, (2007) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 189: 565-573. (Pubitemid 44791225)
43. Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS, (2007) A role for oxytocin and 5-HT 1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine. Neuroscience 146: 509-514. (Pubitemid 46617075)
44. Uvanaes-Moberg K, Ahlenius S, Hillegaart V, Alster P, (1994) High doses of oxytocin cause sedation and low doses cause an anxiolytic-like effect in male rats. Pharmacol Biochem Behav 49: 101-106.
45. Uvanaes-Moberg K, Bjoerkstrand E, Hillegaart V, Ahlenius S, (1999) Oxytocin as a possible mediator of SSRI-induced antidepressant effects. Psychopharmacology 142: 95-101. (Pubitemid 29196069)
46. Verrico CD, Miller GM, Madras BK, (2007) MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189: 489-503. (Pubitemid 44791219)
47. Walker QD, Williams CN, Jotwani RP, Waller ST, Francis R, Kuhn CM, (2007) Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats. Psychopharmacology 189: 435-445. (Pubitemid 44791214)
48. Williams JR, Insel TR, Harbaugh CR, Carter C, (1994) Oxytocin administered centrally facilitates formation of a partner preference in female prairie voles (Microtus ochrogaster). J Neuroendocrinol 6: 247-250. (Pubitemid 24189861)
49. Wolff K, Tsapakis EM, Winstock AR, Hartley D, Holt D, Forsling ML, Aitchison KJ, (2006) Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol 20: 400-410.
50. Zhang L, Barrett JE, (1991) Imipramine as a discriminative stimulus. J Pharmacol Exp Ther 259: 1088-1093.